Actively Recruiting
Imaging Study Using PSMA and FDG PET Scans in Men With Advanced Prostate Cancer to Understand Tumor Biology and Support Treatment Choices
Led by University Health Network, Toronto · Updated on 2026-02-12
30
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying advanced prostate cancer using two types of PET imaging Prostate Specific Membrane Antigen PSMA and 18F-Fluorodeoxyglucose FDG PET scans. The goal is to learn about tumor biology at different disease stages and during treatment, which may help guide future treatment choices and monitor how well treatments work. This study is interventional and sponsored by the University Health Network in Toronto. Participants with advanced prostate cancer will undergo PSMA and FDG PET scans before starting their standard care treatment and again during treatment. The scans use specialized radiotracers including Ga 68 PSMA-11 and 18F-DCFPyL for PSMA imaging and FDG for glucose metabolism imaging. The imaging will help assess tumor activity and changes over time. The study includes monitoring at multiple time points. During the study, participants will receive PET imaging exams and continue their usual care under oncology or urology doctors. Researchers will measure the proportion of patients with high volume metastatic castration-sensitive prostate cancer mCSPC showing PSMA active disease over five years. They will also evaluate the presence of discordant lesions between PSMA and FDG imaging. Participants will be monitored for safety and imaging results throughout the study period, which lasts at least five years.
CONDITIONS
Brief Title
Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer
Research Team
D
Di (Maria) Jiang, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here